|
|
 Previous Article | Table of Contents | Next Article 
Synergistic effects of thrombopoietin and granulocyte colony- stimulating
factor on neutrophil recovery in myelosuppressed mice
A Grossmann, J Lenox, TA Deisher, HP Ren, JM Humes, K Kaushansky and KH Sprugel
ZymoGenetics Inc, Seattle, WA 98102-3702, USA.
Severe suppression of the hematopoietic system is a major factor in
limiting chemotherapy dose escalation. To determine whether a combination
of human recombinant granulocyte colony-stimulating factor (G-CSF) and
thrombopoietin (TPO) would alter recovery of platelets, red blood cells
(RBCs), or neutrophils after myeloablative therapy, myelosuppressed mice
were treated with sc injections of TPO (90 micrograms/kg), G-CSF (250
micrograms/kg). TPO plus G-CSF or vehicle and complete blood counts were
measured. Marrow and spleen cells were obtained at various times and
assayed for erythroid, myeloid, and megakaryocytic progenitors. The
prolonged neutropenia in vehicle controls (14 days) was significantly
shortened in mice treated with G- CSF or TPO for 14 days. The combination
of TPO plus G-CSF further reduced the duration of neutropenia. TPO and TPO
plus G-CSF treatments also significantly shortened thrombocytopenia
compared to vehicle. Recovery of RBCs was also enhanced in mice treated
with either G-CSF or TPO, or the combination. Furthermore, treatment with
G-CSF and/or TPO hastened myeloid, erythroid, and megakaryocyte progenitor
recovery compared to vehicle controls. These results show that the
combination of TPO plus G-CSF acts synergistically to accelerate neutrophil
recovery in myelosuppressed mice and does not compromise the platelet or
RBC response to TPO therapy.
Volume 88,
Issue 9,
pp. 3363-3370,
11/01/1996
Copyright © 1996 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. L. Angiolillo, V. Davenport, M. A. Bonilla, C. van de Ven, J. Ayello, O. Militano, L. L. Miller, M. Krailo, G. Reaman, and M. S. Cairo
A Phase I Clinical, Pharmacologic, and Biologic Study of Thrombopoietin and Granulocyte Colony-Stimulating Factor in Children Receiving Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Recurrent or Refractory Solid Tumors: A Children's Oncology Group Experience
Clin. Cancer Res.,
April 1, 2005;
11(7):
2644 - 2650.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Zhou, X. Kong, and D. I. H. Linzer
Enhanced Recovery from Thrombocytopenia and Neutropenia in Mice Constitutively Expressing a Placental Hematopoietic Cytokine
Endocrinology,
January 1, 2005;
146(1):
64 - 70.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Sawai, K. Koike, H. H. Mwamtemi, S. Ito, Y. Kurokawa, K. Sakashita, T. Kinoshita, T. Higuchi, K. Takeuchi, M. Shiohara, et al.
Thrombopoietin enhances neutrophil production by bone marrow hematopoietic progenitors with the aid of stem cell factor in congenital neutropenia
J. Leukoc. Biol.,
July 1, 2000;
68(1):
137 - 143.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. Archimbaud, O. G. Ottmann, J. A. L. Yin, K. Lechner, H. Dombret, M. A. Sanz, G. Heil, P. Fenaux, W. Brugger, A. Barge, et al.
A Randomized, Double-Blind, Placebo-Controlled Study With Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults With De Novo Acute Myeloid Leukemia
Blood,
December 1, 1999;
94(11):
3694 - 3701.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kaushansky
Thrombopoietin
N. Engl. J. Med.,
September 10, 1998;
339(11):
746 - 754.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Neelis, T. P. Visser, W. Dimjati, G. R. Thomas, P. J. Fielder, D. Bloedow, D. L. Eaton, and G. Wagemaker
A Single Dose of Thrombopoietin Shortly After Myelosuppressive Total Body Irradiation Prevents Pancytopenia in Mice by Promoting Short-Term Multilineage Spleen-Repopulating Cells at the Transient Expense of Bone Marrow-Repopulating Cells
Blood,
September 1, 1998;
92(5):
1586 - 1597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Matsunaga, T. Kato, H. Miyazaki, and M. Ogawa
Thrombopoietin Promotes the Survival of Murine Hematopoietic Long-Term Reconstituting Cells: Comparison With the Effects of FLT3/FLK-2 Ligand and Interleukin-6
Blood,
July 15, 1998;
92(2):
452 - 461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Shibuya, H. Akahori, K. Takahashi, E. Tahara, T. Kato, and H. Miyazaki
Multilineage Hematopoietic Recovery by a Single Injection of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor in Myelosuppressed Mice
Blood,
January 1, 1998;
91(1):
37 - 45.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Abraham and R. L. Basser
Megakaryocyte Growth and Development Factor: A Review of Early Clinical Studies
Oncologist,
October 1, 1997;
2(5):
311 - 318.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
